Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24953654 | 0.90 | TRPM8 (0.38) | JAK2JAK1JAK3RAB9A | |
| SCHEMBL24953926 | 0.90 | TRPM8 (0.38) | JAK2JAK1JAK3RAB9A | |
| SCHEMBL28854659 | 0.90 | TRPM8 (0.38) | JAK2JAK1JAK3RAB9A | |
| SCHEMBL24952895 | 0.89 | JAK2 (0.40) | JAK2JAK1JAK3HRH3GCK | |
| SCHEMBL24954128 | 0.88 | CYP3A4 (0.34) | GCK | |
| SCHEMBL24954291 | 0.88 | KCNH2 (0.34) | GCKNPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL24953942 | 0.88 | KDR (0.36) | GCK | |
| SCHEMBL24953924 | 0.87 | GCK (0.35) | GCK | |
| SCHEMBL24953728 | 0.87 | GCK (0.35) | GCK | |
| SCHEMBL24953890 | 0.87 | CCNE1 (0.46) | NPC1TP53RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | DERMIRA, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029266-A1 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | MRGPRX2, MRGPRX1, MRGPRX4 | JAK2 2734/4885JAK1 3663/4885JAK3 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.